Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration.
Seki
Nobuhiko
N
Uematsu
Kazutsugu
K
Shibakuki
Reishi
R
Eguchi
Kenji
K
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D004334:Drug Administration Schedule; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000502:physiology; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib